|Continuum Health Partners: Beth Israel • Roosevelt Hospital and St. Luke's Hospital • Long Island College Hospital • New York Eye and Ear Infirmary|
|Home | Find A Doctor | Contact Us|
A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion.
The purpose of this study is to see if adding the oral chemotherapy pill, sorafenib (Nexavar), to localized chemotherapy (chemoembolization) to the liver will help patients to live longer than treatment with localized chemotherapy to the liver without sorafenib. Sorafenib is currently approved by the United States Food and Drug Administration for the treatment of liver cancer. It is not known if the combination of chemoembolization and sorafenib will work better than chemoembolization alone.
Subjects eligible for this study will receive 1 of 2 treatments:
ARM A: Sorafenib + Chemoembolization
ARM B: Placebo + Chemoembolization
Copyright © 2008